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Objectives and methods: Klebsiella pneumoniae is a nosocomial pathogen and is considered the most
common Gram-negative bacterium that exhibits multiple antimicrobial resistances. In this study, the
transfer of antimicrobial resistance genes from the clinical multiresistant K. pneumoniae MGH75875
isolate was assessed in vitro and in vivo in an intestinal colonization animal model. The ability to colo-
nize and transfer was tested under different antimicrobial treatments. The frequency of the horizontal
gene transfer was also examined in vitro.
Results: The clinical isolate of K. pneumoniae colonized the intestine of mice at levels up to
10
9 cfu/g faeces in antimicrobial-treated mice. In mice without antimicrobial treatment, the strain
quickly decreased to below the detection limit due to competitive exclusion by the indigenous mouse
ﬂora. Onset of antimicrobial treatment gave immediate rise to detectable levels of the strain in the
faeces of up to 10
9 cfu/g faeces. The experiment clearly shows that the treatment selects resistant
strains and gives advantages to colonize the gastrointestinal tract. Furthermore, high transfer fre-
quency of different plasmids was observed during colonization of the mouse intestine. The blaSHV and
blaTEM genotypes were transferred to both an indigenous recipient in the in vivo setting and to an
MG1655 Escherichia coli recipient strain in vitro.
Conclusions: K. pneumoniae is an excellent colonizer of the intestine and is extremely promiscuous
with respect to the transferability of its numerous plasmids. Antimicrobial treatment enhances the
selection of resistant strains and results in an increase in the resistance gene pool, which ultimately
raises the risk of spreading resistance genes.
Keywords: MGH78578, horizontal gene transfer, streptomycin-treated mice, gastrointestinal tract,
indigenous ﬂora, selective pressure
Introduction
Klebsiella pneumoniae is a common Gram-negative bacterium
that exhibits multiple antimicrobial resistances.
1 K. pneumoniae is
also an important opportunistic pathogen, and many studies
observe K. pneumoniae as the most common source of Gram-
negative nosocomial bacteraemia.
2,3 Recently, pyogenic liver
abscess was linked to K. pneumoniae in several cases.
4,5
Furthermore, 15% to 30% of the multiresistant K. pneumoniae
isolates are resistant to broad-spectrum cephalosporins via
plasmid-encoded extended-spectrum b-lactamases (ESBLs).
6
K. pneumoniae is ubiquitous; the natural habitat includes soil,
vegetation and surface waters and the intestinal mucosal surface
of mammals.
7 In a clinical setting, the most important reservoirs
for transmission are assumed to be the gastrointestinal tracts of
patients and the hands of the personnel.
8 It has been shown
that the majority of the infections in the urinary and/or in the
respiratory tract are preceded by the colonization of the patients’
gastrointestinal tract by the pathogen.
9 This observation combined
with the well-known hypothesis ‘that the human colon is serving
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10 Transfer of resistance genes among potentially pathogenic
bacteria in the gastrointestinal tract results in multiresistant
bacteria that might cause infections to spread to different organs
and ultimately result in treatment failure.
The goal of the present study was to investigate the transfer
of antimicrobial resistance genes in the gastrointestinal tract.
The gene transfer was studied in vitro and in vivo in the intestine
of mice treated with antimicrobial agents from a multiresistant
clinical K. pneumoniae isolate to a susceptible Escherichia coli
strain.
Materials and methods
Bacterial strains and media
K. pneumoniae MGH78578 (ATCC 700721) is a clinical isolate from
an intensive care unit (ICU) patient with pneumonia. The strain is
resistant to numerous antimicrobial agents, including ampicillin,
streptomycin, tetracycline, nalidixic acid, ticarcillin, trimethoprim/
sulfamethoxazole, cefotaxime and gentamicin, and is susceptible to
imipenem. The strain contains ﬁve plasmids of 176, 108, 89, 4 and
3 kb. Derivatives of the E. coli K12 strain MG1655 were used as reci-
pients in the transfer experiments.
11 A spontaneous streptomycin- and
rifampicin-resistant mutant (MG1655SR) and a streptomycin- and
nalidixic acid-resistant mutant (MG1655SN) were used as recipients
in the transfer experiments. All strains were grown in Luria–Bertani
(LB) medium (Sigma, St Louis, MO, USA) at 378C overnight.
Unless otherwise stated, the antimicrobial agents and chemicals
used in this study were of analytical grade and were obtained from
Sigma. Rifampicin was purchased from Fluka BioChemica, Buchs,
Switzerland.
Transfer of antimicrobial resistance genes in vitro
Overnight cultures of donor and recipient strains were mixed in a
ratio of 1:1, and the mixture was washed in saline (0.9% NaCl). An
aliquot of 20 mL of the mixture was spotted on an LB plate incu-
bated at 378C for 24 h and plated on selective plates. Selective
plates used for K. pneumoniae MGH75578 and E. coli MG1655SR
contained 100 mg/L streptomycin sulphate, 200 mg/L rifampicin
(for recipient þ transconjugant), 50 mg/L ampicillin, 50 mg/L
kanamycin (for donor þ transconjugant), 100 mg/L streptomycin
sulphate, 200 mg/L rifampicin, 50 mg/L ampicillin or 50 mg/L
kanamycin or 20 mg/L chloramphenicol or 10 mg/L tetracycline or
15 mg/L nalidixic acid (for transconjugants).
Antimicrobial-treated mouse model of gastrointestinal tract
colonization
Six- to eight-week-old, outbred albino female Ssc:CF1 mice
[Statens Serum Institut (SSI), Copenhagen, Denmark] were used for
colonization and antimicrobial resistance transfer studies. The mice
were individually caged, and cages were changed daily. The mice
had unlimited access to food and continuously received either pure
drinking water or water containing antimicrobial agents, either strep-
tomycin sulphate or ampicillin.
12 Prior to inoculation, faecal
samples were tested for the presence of indigenous bacteria with
similar resistance. Inoculum suspensions were prepared by
10  overnight cultures resuspended in 20% (w/v) sucrose. Each
mouse was given 100 mL of suspension per os. Faecal samples were
collected and the numbers of cfu were determined by serial dilution
and spread on selective plates. The mice were euthanized, and the
experimental duration time was between 3 and 6 weeks. All experi-
ments were performed twice independently. The animal experiments
were approved by The Animal Experiments Inspectorate, The
Danish Ministry of Justice, and were performed by skilled person-
nel. Different antimicrobial concentrations were tested, and the
lowest concentration that allowed Klebsiella MGH78578 to colonize
was selected.
Effects of antimicrobial treatment on intestinal ﬂora
Three mice per experiment were inoculated with the strain
K. pneumoniae MGH78578 (2   10
9 cfu/mouse). The mice were
provided with fresh drinking water every day. The numbers of cfu
in faecal samples were determined on LB plates containing 50 mg/L
ampicillin and 25 mg/L kanamycin. To mimic the treatment of
infection, 0.5 g/L ampicillin was added to the drinking water
4 weeks after inoculation.
Colonization of the intestine during antimicrobial treatment
Two mice per experiment were treated with 0.5 g/L ampicillin in the
drinking water prior to inoculation of the strain K. pneumoniae
MGH78578 (1   10
9 cfu/mouse) and throughout the experiment.
The numbers of cfu were determined from faecal samples homogen-
ized and spread on LB plates containing 50 mg/L ampicillin and
25 mg/L kanamycin.
Gene transfer in the intestine of streptomycin-treated mice
Three mice per experiment were treated with 0.5 g/L streptomycin
sulphate in the drinking water prior to inoculation with the recipient
strain and throughout the experiment. The recipient E. coli
MG1655SR was given per os at 3   10
8 cfu/mouse. The recipient
strain was allowed to establish in the intestine for 1 week before
inoculation of the donor K. pneumoniae MGH78578 (3   10
8 cfu).
The numbers of cfu were determined from faecal samples on LB
plates containing: 100 mg/L streptomycin and 50 mg/L rifampicin
(for recipients þ transconjugants), 50 mg/L ampicillin and 25 mg/L
kanamycin (for donors þ transconjugants) and 100 mg/L strepto-
mycin and 50 mg/L rifampicin with 25 mg/L ampicillin or 25 mg/L
kanamycin or 10 mg/L chloramphenicol (for transconjugants).
Veriﬁcation of transconjugants
Biochemical assays. Bacterial species were veriﬁed on selective media
and by biochemical tests: Statens Serum Institut (SSI) blue plates with
lactose (SSI nr. 694, Hillerød, Denmark) were used to select
Gram-negative bacilli; 4-nitro-phenyl-b-D-glukopyranosiduronic acid
test (a b-glucuronidase activity test; SSI nr. 1033, Hillerød, Denmark)
to differentiate K. pneumoniae from E. coli; and saccharose test
(SSI nr. 3734, Hillerød, Denmark) to detect the indigenous E. coli
transconjugants.
Plasmid proﬁle. Plasmid preparation was conducted by a modiﬁ-
cation of a previously described method.
13 Brieﬂy, 1 mL of over-
night culture was centrifuged for 5 min at 5000 g. The pellet was
resuspended in 20 mL of TE buffer [50 mM Tris–HCl and 1 mM
EDTA (pH 8.0)] and lysed by adding 100 mL of lysis buffer (3%
SDS, 80 mM NaOH and 50 mM Tris–HCl). The suspension was
vortexed carefully (2 s) and incubated at 568C for 30 min, and then
100 mL of phenol mixture (phenol/chloroform/isoamyl alcohol,
25:24:1) was added. The sample was vortexed (3   3 s) and
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ferred to a new tube and mixed with the loading buffer. The
plasmid proﬁles were run on a 0.8% agarose gel and visualized by
ethidium bromide staining. As a plasmid size marker, E. coli
39R861 was used, containing four plasmids of 147, 63, 36 and
7 kb.
14
Pulsed-ﬁeld gel electrophoresis. PFGE analysis was performed
according to the Pulse-Net standard protocol, with restriction
enzyme XbaI (Roche, Indianapolis, IN, USA) and Salmonella
Branderup strain used as a molecular weight marker.
15
Antimicrobial susceptibility testing. All strains, donors, recipients
and transconjugants were tested for their antimicrobial resistance
proﬁle either by disc diffusion or by Etest as follows.
Disc diffusion was conducted on Speciﬁc agar plate (SSI nr.
22879, Hillerød, Denmark) and adding Neo-Sensitabs (Rosco
Diagnostica, Taastrup, Denmark) followed by incubation at 378C for
24 h. Diameters of the zones were measured and analysed according
to Rosco manual V (Rosco Diagnostica, 2008). The antimicrobial
concentrations tested were: amikacin, 40 mg; ampicillin, 33 mg;
cefotaxime, 30 mg; chloramphenicol, 60 mg; ciproﬂoxacin, 10 mg;
gentamicin, 40 mg; imipenem, 18 mg; kanamycin, 100 mg; mecilli-
nam, 33 mg; nalidixic acid, 130 mg; nitrofurantoin, 260 mg; poly-
myxins, 150 mg; rifampicin, 30 mg; sulphonamide, 240 mg;
tetracycline, 80 mg; tobramycin, 40 mg; and trimethoprim, 5.2 mg.
ESBL-producing phenotypes were conﬁrmed with Etest strips
(AB Biodisk, Solna, Sweden), which were applied on Mueller–
Hinton plates (SSI nr. 708, Copenhagen, Denmark) with cefotaxime
(CTX) and cefotaxime þ clavulanic acid (CTX þ CLA), and cefta-
zidime (CAZ) and ceftazidime þ clavulanic acid (CAZ þ CLA).
Etest was read according to the manufacturer’s protocol after over-
night incubation at 378C.
PCR detection of ESBL genes. The primers that were used to
check for the presence of ESBL genes were: blaTEM genes,
F5 0-GTATCCGCTCATGAGACAATAACCCTG-30,R5 0-CCAATGC
TTAATCAGTGAGGCACC-30; blaSHV genes, F 50-CGCCTGTGTA
TTATCTCCCTGTTAGCC-30,R5 0-TTGCCAGTGCTCGATCAGC
G-30; blaOXA genes, F 50-ATGAAAACATTTGCCGCATATGTA-30,
R5 0-ACACCAGGATTTGACTCAGTTCC-30 and blaCTX-M genes,
F5 0-ATGGCGGCCGCGGCGGTGCTTAA-30,R5 0-AGCGCGGCC
GCGCTACAGTACAGC-30.
16 The strains used as positive/negative
controls were: blaTEM (K. pneumoniae KP6T
17/E. coli K12J62-2),
blaSHV (K. pneumoniae KP15
17/E. coli ATCC 25922), blaOXA
(E. coli J53-2/pm202
18/E. coli MG1655) and blaCTX-M (K. pneumo-
niae KP4aC
17/E. coli K12J62-2). Amplitaq polymerase (5 U/mL)
and boiling lysate were used. All PCR ampliﬁcations were per-
formed in a T3 Thermocycler (Biometra, Go ¨ttingen, Germany)
using the following PCR programme: 3 min at 948C; 29 cycles of
30 s at 948C, 30 s at 608C( tem), 628C( shv), 568C( oxa) and 658C
(ctx-m) and 60 s at 728C; and 10 min at 728C.
16 The PCR products
were run on a 2% E-gel (Invitrogen, Carlsbad, CA, USA).
Results
Susceptibility testing of K. pneumoniae MGH78578
The MGH78578 strain was characterized in our laboratory
for the presence of ESBL and was found to be resistant towards
cefpodoxime. Etest conﬁrmed an ESBL-producing phenotype
(CTX/CTX þ CLA ¼ phantom inhibition of zone/0.064 and
CAZ/CAZ þ CLA ¼ .32/.4 ¼ out of range). The K. pneumoniae
strain was further tested and found to possess two b-lactamase
genes, tem and shv, revealed by PCR (data not shown).
Transfer of antimicrobial resistance genes in vitro
The ability of the clinical strain K. pneumoniae MGH78578 to
transfer its antimicrobial resistance genes was studied in vitro.
K. pneumoniae MGH78578 was used as a donor and E. coli
MG1655SR was used as a recipient. Transconjugants were
detected on plates containing streptomycin, rifampicin and
either ampicillin or kanamycin after both solid and broth
mating. The transfer frequency obtained was 1.3–1.9   10
25
transconjugants/recipient from mating on plates and 1.1–
1.8   10
24 from mating in liquid media.
All transconjugants were tested against a number of anti-
biotics and were found to be resistant to ampicillin, kanamycin
and cefpodoxime, and intermediately resistant to amikacin, cefo-
taxime and tobramycin (Table 1, TC MG vitro 2). The plasmid
proﬁles showed that the transconjugants had obtained the second
largest plasmid from the donor (Figure 1a, lane 5). ESBL Etest
conﬁrmed ESBL phenotype (CTX/CTX þ CLA ¼ deformation
of CTX zone/0.016 and CAZ/CAZ þ CLA ¼ deformation of
CAZ zone/0.064) and PCR showed the presence of two ESBL
genes, shv and tem (data not shown). A few of the transconju-
gants were seen to harbour the largest plasmid from the donor
strain and exhibited resistance towards ampicillin, kanamycin,
chloramphenicol, tobramycin, trimethoprim and sulphonamide,
and intermediate resistance towards gentamicin and amikacin
(Figure 1a, lane 4 and Table 1, TC MG vitro 1). The PFGE pro-
ﬁles veriﬁed that the transconjugants were MG1655SR
(Figure 1b, lanes 2, 4 and 5).
Effects of antimicrobial treatment on colonization
of the intestine by K. pneumoniae
The colonization ability of the clinical isolate of K. pneumoniae
and persistence in the gut was investigated using mice with
normal ﬂora. In this experiment, three mice were provided with
drinking water without antimicrobial agents, and on day 0,
the mice were inoculated with K. pneumoniae MGH78578
(2   10
9 cfu/mouse). Only 1 day after inoculation, the level of
the strain was reduced to 10
4–10
5 cfu/g faeces (Figure 2), and
from day 6, K. pneumoniae was only detectable in two mice.
After day 16, the level of the strain was below the detection limit
(DL ¼ 50 cfu/g faeces, corresponding to the minimum number of
detectable colonies when 200 mL is plated) in all three mice and
remained undetected. To investigate the effects of antimicrobial
treatment and to mimic a clinical setting, 0.5 g/L ampicillin was
added to the drinking water at day 28 and throughout the rest of
the experiment. The cfu levels of the strain quickly rose above the
detection limit and colonized the intestine at a high level of
 10
9 cfu/g faeces for the rest of the experiment (Figure 2).
Colonization of the intestine during continuous
antimicrobial treatment
The mouse model was used to investigate the colonization
ability of K. pneumoniae during the antimicrobial treatment with
ampicillin. Prior to inoculation with K. pneumoniae, faeces from
mice were tested for the presence of indigenous bacteria resistant
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1088Table 1. Resistance and plasmid proﬁles of recipient, donor and transconjugants
Transconjugants
Recipient Donor TC MG vitro 1T C M G vitro 2T C I G E. coli vivo TC MG vitro 3T C M G vivo
MG MGH (MGH þ MG vitro) (MGH þ MG vitro) (MGH þ ﬂora vivo)( T C I G E. coli þ MG vitro) (MGH þ MG vivo)
Plasmids 0 5 1 (176 kb) 1 (108 kb) 1 (108 kb) 1 (108 kb) 1 (89 kb)
Antibiotic
amikacin S II I I I I
chloramphenicol S RR SS S R
gentamicin S II SS S S
kanamycin S RR R R R R
streptomycin R R R R I R R
tetracycline S R S S S S S
tobramycin S RR I I I S
ampicillin S RR R R R R
cefotaxime S R S II I S
cefpodoxime S R S RR R S
imipenem S S S S S S S
mecillinam S R S S S S S
ciproﬂoxacin S I S S S S S
nalidixic acid S R S S S S S
rifampicin R I R R I R R
sulphonamide S RR SS S S
trimethoprim S RR SS S S
polymyxins S I S S S S S
nitrofurantoin S I S S S S S
Donor: K. pneumoniae, MGH; recipient: E. coli, MG; ﬂora vivo: natural ﬂora of mice in colonizing experiment; IG, indigenous; TC, transconjugant; R, resistance; I, intermediate resistance; S, susceptible;
bold indicates resistance transferred from the donor.
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9towards ampicillin and kanamycin—no bacteria were detected
on the selective plates. On day 0, the mice were inoculated with
MGH78578 (1   10
9 cfu/mouse), which colonized the intestine
in high numbers 10
7–10
10 cfu/g faeces (Figure 3). At day 23,
non-mucoid colonies were noticed on the selective plates
(containing ampicillin and kanamycin) at levels of 3   10
8–
4   10
9 cfu/g faeces. Biochemistry assays identiﬁed the
unknown colony to be an E. coli that is able to grow on the
selective plates. The indigenous E. coli and the Klebsiella
strains co-colonized the intestine throughout the experiment
(Figure 3). The indigenous E. coli was resistant to ampicillin,
kanamycin and cefpodoxime, and intermediately resistant to
amikacin, cefotaxime and tobramycin, which is an antimicrobial
proﬁle similar to that of K. pneumoniae MGH78578 (Table 1,
TC IG E. coli vivo). The indigenous E. coli strain was also con-
ﬁrmed ESBL-positive with Etest ESBL (CTX/CTX þ CLA ¼
deformation of CTX zone/0.032 and CAZ/CAZ þ CLA ¼
12 3 4 5 6 7 8
147-
63-
36-
7-
Kb
(a) (b)
104 -
Kb
1135 -
452.7 -
54.7 -
216.9 -
12 3456 7 8
Figure 1. Plasmid proﬁles and PFGE proﬁles of donor, recipient and transconjugants. (a) Plasmid proﬁles where the marker is E. coli 39R861 (147, 63, 37
and 7 kb).
12 (b) PFGE proﬁles using the restriction enzyme XbaI and Salmonella Branderup strain as a molecular weight marker. Lane 1, marker; lane; 2,
recipient E. coli MG1655SR; lane 3, donor K. pneumoniae MGH75875; lanes 4–8, transconjugants (TCs) from different experiments (lane 4, TC MG vitro 1;
lane 5, TC MG vitro 2; lane 6, TC indigenous E. coli vivo; lane 7, TC MG vitro 3; and lane 8, TC MG vivo).
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Figure 2. cfu counts of K. pneumoniae from faecal samples of mice. Arrow
indicates the shift in drinking water from 0 to 0.5 g/L ampicillin (AMP). The
detection limit is illustrated by the dashed line. cfu of the inoculation
suspension is shown at day 0 (2   10
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Figure 3. cfu counts of K. pneumoniae from faecal samples of mice treated
with 0.5 g/L ampicillin. The level of K. pneumoniae (ﬁlled squares and ﬁlled
triangles) and indigenous E. coli transconjugants in Mouse 1 and 2 (open
squares and open triangles). cfu of the inoculation suspension is shown at
day 0 (1   10
9 cfu/mouse).
Schjørring et al.
1090deformation of CAZ zone/0.064). ESBL PCR revealed the pre-
sence of shv and tem genes, which were also present in the K.
pneumoniae strain used for colonization (data not shown). A
plasmid proﬁle revealed that the indigenous E. coli contained a
plasmid of  108 kb (Figure 1a, lane 6), which corresponds to
the second largest plasmid in the MGH78578 strain—the indi-
genous E. coli was in fact a transconjugant.
The indigenous E. coli transconjugant was used as a donor in
order to assess the transferability of resistance genes. The indi-
genous E. coli transconjugant showed good ability of secondary
transfer to recipient E. coli MG1655SR. The frequency of trans-
fer in the liquid mating experiment was 1.26   10
23 transconju-
gants/recipient on average; however, no transconjugants were
detected from mating on solid media. Plasmid and resistance
proﬁles were as expected—plasmid of 108 kb (Figure 1a, lane 7)
and resistance to ampicillin, kanamycin and cefpodoxime, and
intermediate resistance towards amikacin, cefotaxime and tobra-
mycin (Table 1, TC MG vitro 3). ESBL was conﬁrmed with
Etest (CTX/CTX þ CLA ¼ deformation of CTX zone/0.016 and
CAZ/CAZ þ CLA ¼ deformation of CAZ zone/0.064) and ESBL
PCR gave shv and tem genes (data not shown). The PFGE proﬁle
of the indigenous E. coli transconjugants veriﬁed the difference
from MG1655 (Figure 1b, comparing lanes 2 and 6). The trans-
conjugants from the secondary transfer study showed a proﬁle
identical to the transconjugants obtained from the conjugation
between Klebsiella MGH78578 and MG1655SR in vitro—
containing the ESBL genes (Figure 1b, lanes 5 and 7). Comparing
all three transconjugant PFGE proﬁles (Figure 1b, lanes 5–7),
there are similarities around the marker size 104 kb, which is con-
sistent with the size of the plasmid containing the ESBL genes.
Gene transfer in the intestine of streptomycin-treated mice
To explore the transferability of the clinical K. pneumoniae
strain to a speciﬁc E. coli, the streptomycin-treated mouse
model was used. The mice were tested prior to inoculation and
no resistant bacteria were present in faeces either before or
after 24 h of streptomycin treatment. The recipient E. coli
MG1655SR (3   10
8 cfu/mouse) was inoculated 1 week prior to
the donor MGH78578 (3   10
8 cfu/mouse) to allow the strain to
colonize the intestine. The recipient E. coli strain colonized the
gut at a level of 10
7 cfu/g faeces throughout the experiment
(Figure 4). The donor was inoculated at day 8 and colonized the
intestine at 10
8–10
9 cfu/g faeces. Transconjugants in all three
mice were detected the day after introduction of the donor and
colonized throughout the experiment. The level of transconju-
gants was equal to that of the recipients, suggesting that all reci-
pients become transconjugants (Figure 4).
Transconjugants were veriﬁed by plasmid and resistance pro-
ﬁles. The isolated transconjugants showed identical resistance
proﬁles and all contained a large plasmid of  89 kb, which cor-
responds to the third largest plasmid in the donor strain
(Figure 1a, lane 8). Resistance patterns showed resistance towards
ampicillin, kanamycin and chloramphenicol, and intermediate
resistance towards amikacin as the donor strain (Table 1, TC MG
vivo). The transconjugants from the in vivo conjugation experi-
ments were able to re-transfer the plasmid to a nalidixic acid-
resistant E. coli MG1655 derivate at a frequency of 1.94   10
22
transconjugants/recipients from mating in liquid media. All tested
transconjugants showed resistance proﬁles and plasmid proﬁles as
expected—resistance towards ampicillin, kanamycin and chlor-
amphenicol, and intermediate resistance towards amikacin (data
not shown).
Discussion
K. pneumoniae is a nosocomial pathogen often isolated from
ICU patients. Outbreak of Klebsiella in ICUs has been described
relatively frequently;
19–22 a recent cohort study observed that
52% of the K. pneumoniae infection was caused by patient-to-
patient transmission.
23 K. pneumoniae MGH78578, a clinical
isolate, was used to investigate the colonization ability of an
opportunistic pathogen to colonize the gastrointestinal tract with
and without antimicrobial treatment and to investigate whether
the antimicrobial resistance genes are transferred in the gastroin-
testinal tract.
In this study, it was experimentally shown that antimicrobial
treatment provides a major advantage to bacteria harbouring anti-
microbial resistance genes. Thus, it was shown that K. pneumoniae
was able to proliferate quickly from undetectable numbers and
colonize the gut in high numbers within a few days, during the
antimicrobial treatment (Figure 2). This experimental model
mimicking a patient treated with antimicrobial agents revealed a
time line that indeed explains how patients, admitted to hospi-
tals, within days of antimicrobial treatment get colonized with
resistant strains—resistant to the antimicrobial agents given as
therapy. Graffunder et al.
24 also concluded that giving third-
generation cephalosporins or aminoglycosides is a risk factor
that enhances the acquisition of ESBL bacteria by adding selec-
tive pressure.
Besides the selection of antimicrobial-resistant strains during
therapy, K. pneumoniae transferred plasmids containing resist-
ance genes to an indigenous E. coli. The transferability of these
plasmids was assessed in the in vivo model using E. coli
MG1655SR as a speciﬁc recipient. Transconjugants were
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Figure 4. cfu counts of donor and recipient inoculated in three mice treated
with 0.5 g/L streptomycin. Recipient E. coli MG1655SR (ﬁlled circles) was
inoculated ﬁrst, and at day 7, the clinical K. pneumoniae strain (ﬁlled
triangles) was introduced. Transconjugants (TCs) selected on different
media: rifampicin and ampicillin (ﬁlled upside-down triangles), rifampicin
and kanamycin (ﬁlled diamonds), and rifampicin and chloramphenicol
(ﬁlled circles). cfu of the inoculation suspension of E. coli MG1655SR
shown at day 0 (3   10
8 cfu/mouse) and inoculation suspension of
K. pneumoniae at day 7 (3   10
8 cfu/mouse) (not depicted).
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level of 10
6–10
8 cfu/g faeces. All the transconjugants contained
a common large plasmid (89 kb) from K. pneumoniae strain
resistant to ampicillin, kanamycin and chloramphenicol and
intermediately resistant to amikacin.
Furthermore, we found that which plasmids are transferred is
inﬂuenced by environmental conditions (in vitro versus in vivo).
In vitro experiments showed transfer of the 108 or 157 kb
plasmid, while the in vivo conjugation experiment showed
transfer of the 89 kb plasmid. Nevertheless, transfer of the
108 kb plasmid was also observed in the ﬁrst in vivo colonizing
experiment where the plasmid was transferred to the indigenous
E. coli.
Plasmids from the clinical K. pneumoniae strain were seen to
be highly conjugative. Thus, both plasmids (89 and 108 kb)
were transferred at high frequency to another recipient E. coli.
This also shows that the plasmids are conjugative on their own.
Transfer of antimicrobial resistance genes has been investi-
gated by different methods, both in vitro (ﬁlter, plate and
liquid mating)
25,26 and in animals—‘worst-case’ models such as
gnotobiotic rats or mice,
27–30and conventional colonization models
such as the streptomycin-treated mice used in this study.
31,32
Using the animal model containing normal bacteria, ﬂora gives
more realistic results than any in vitro or gnotobiotic study. The
normal bacterial ﬂora barrier and the present immune system
give the used animal model advantages in mimicking the human
gastrointestinal tract. Transfer in vivo cannot be calculated from
the extrapolation of in vitro experiments.
The indigenous ﬂora can act as a reservoir and transfer resist-
ance genes to pathogenic bacteria that might lead to infections
with limited treatment possibilities. Transfer of any anti-
microbial resistance genes is a threat, but transfer of ESBL resist-
ance genes is in a category of its own, which might result in the
limitation of treatment and in worst cases treatment failure.
33,34
Transfer of ESBL shv and tem genes from K. pneumonia to
E. coli was obtained both in in vitro and in vivo studies—an
illustration of how quickly ESBL genes can be spread.
The fact that transfer of antimicrobial resistance genes
happens in patients has been previously reported by Karami
et al.
35 where transfer of ampicillin resistance genes between
two E. coli strains was observed in the gastrointestinal tract of
infants. Also, Bidet et al.
36 described plasmid pACC-1 harbour-
ing a b-lactamase resistance gene being transferred from
K. pneumoniae to an E. coli during the antimicrobial treatment
of infants. Our studies clearly show that transfer can occur at a
relatively high level in the gastrointestinal tract of mice.
This study also clearly shows that resistant strains can be
present in the gastrointestinal tract at a low level, and after the
antimicrobial treatment, they can be selected to colonize the
intestine. The ecological effect of antimicrobial treatment on
the commensal microﬂora warrants further study in the future.
The rational use of antimicrobial agents together with infection
control will aid in controlling further spread of these multiresis-
tant bacteria.
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